Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2016 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Dennis M, Burnett A, Hills R, Thomas I, Ariti C, Severinsen MT, Hemmaway C, Greaves P, Clark RE, Copland M, Russell N; National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group. Dennis M, et al. Br J Haematol. 2021 Jul;194(2):298-308. doi: 10.1111/bjh.17501. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33961292 Clinical Trial.
Older patients with acute myeloid leukaemia (AML) account for nearly half of those with the disease. ...Despite promising pre-clinical, early non-randomised clinical data with acceptable toxicity and an improvement in response, we did not find evidence …
Older patients with acute myeloid leukaemia (AML) account for nearly half of those with the disease. ...Despite …
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH; UK National Cancer Research Institute AML Working Group. Burnett AK, et al. Leukemia. 2013 Jan;27(1):75-81. doi: 10.1038/leu.2012.229. Epub 2012 Aug 14. Leukemia. 2013. PMID: 22964882 Clinical Trial.
The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensive therapy, is unsatisfactory. ...
The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensiv …
Assessment of Minimal Residual Disease in Standard-Risk AML.
Hills RK, Ivey A, Grimwade D; UK National Cancer Research Institute (NCRI) AML Working Group. Hills RK, et al. N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. N Engl J Med. 2016. PMID: 27509124 Free article. No abstract available.